You are here

Keytruda

ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients

ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients

Fierce Pharma

clinical trials

colorectal cancer

Flag link:

ASCO 2020 – first-line lung cancer focus

ASCO 2020 – first-line lung cancer focus

EP Vantage

Bristol-Myers Squibb

Flag link:

ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no

ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no

Fierce Pharma

extensive-stage small cell lung cancer

Flag link:

Merck grabs FDA green light for less-frequent Keytruda dosing regimen

Merck grabs FDA green light for less-frequent Keytruda dosing regimen

Fierce Pharma

Flag link:

Merck builds case for six-week Keytruda dosing as FDA starts review

Merck builds case for six-week Keytruda dosing as FDA starts review

Pharmaforum

Flag link:

Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck

Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck

BioSpace

triple negative breast cancer

Flag link:

FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ use

FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ use

Pharmaforum

tumor agnostic drugs

Flag link:

Seattle Genetics Issue Update on Padcev Label Expansion Study

Seattle Genetics Issue Update on Padcev Label Expansion Study

Yahoo/Zacks.com

Seattle Genetics

urothelial cancer

Flag link:

Merck scores new advance on tumor-agnostic front as Keytruda beat chemo-based regimens in a type of colorectal cancer

Merck scores new advance on tumor-agnostic front as Keytruda beat chemo-based regimens in a type of colorectal cancer

Endpoints

colorectal cancer

Flag link:

FDA Rejects Merck's 6-Week Dosing Schedule for Keytruda

FDA Rejects Merck's 6-Week Dosing Schedule for Keytruda

BioSpace

Flag link:

Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer

Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer

Endpoints

triple negative breast cancer

clinical trials

Flag link:

BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market

BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market

BioSpace

non-small cell lung cancer

Flag link:

Merck's Blockbuster Drug Wins Key New FDA Approval

Merck's Blockbuster Drug Wins Key New FDA Approval

Motley Fool

Flag link:

US cancer death rate drops by sharpest rate on record

US cancer death rate drops by sharpest rate on record

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Merck’s Keytruda Shows Mixed Results in Lung Cancer Study

Merck’s Keytruda Shows Mixed Results in Lung Cancer Study

BioSpace

small cell lung cancer

Flag link:

Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK

Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK

Fierce Pharma

Flag link:

Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Motley Fool

Flag link:

Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

Fierce Pharma

nadofaragene firadenovec

Flag link:

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

Pharmaceutical Business Review

priority review

Flag link:

Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst

Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst

Fierce Pharma

non-small cell lung cancer

Flag link:

Pages